The role of methotrexate in osteosarcoma

Jean L. Grem; Susan A. King; Robert E. Wittes; Brian Leyland-jones

doi:10.1093/jnci/80.9.626

The role of methotrexate in osteosarcoma

Jean L. Grem, Susan A. King, Robert E. Wittes, Brian Leyland-jones

Research output: Contribution to journal › Review article › peer-review

46 Scopus citations

Abstract

High-dose methotrexate (MTX) is one of the agents currently used in intensive adjuvant chemotherapy regimens for nonmetastatic osteosarcoma. To elucidate the role of high-dose MTX in this disease, we present the history of trials conducted with MTX from the first single-agent studies through progressively complex combination regimens. With this background, some of the basic dissues concerning MTX therapy in osteosarcoma are discussed. [J Natl Cancer Inst 1988;80:626-656].

Original language	English (US)
Pages (from-to)	626-655
Number of pages	30
Journal	Journal of the National Cancer Institute
Volume	80
Issue number	9
DOIs	https://doi.org/10.1093/jnci/80.9.626
State	Published - Jul 6 1988
Externally published	Yes

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1093/jnci/80.9.626

Cite this

@article{66a16eddcdda41c5a22eeb9bd675cf99,

title = "The role of methotrexate in osteosarcoma",

abstract = "High-dose methotrexate (MTX) is one of the agents currently used in intensive adjuvant chemotherapy regimens for nonmetastatic osteosarcoma. To elucidate the role of high-dose MTX in this disease, we present the history of trials conducted with MTX from the first single-agent studies through progressively complex combination regimens. With this background, some of the basic dissues concerning MTX therapy in osteosarcoma are discussed. [J Natl Cancer Inst 1988;80:626-656].",

author = "Grem, {Jean L.} and King, {Susan A.} and Wittes, {Robert E.} and Brian Leyland-jones",

note = "Funding Information: {"}Received November 23, 1987; accepted January 5, 1988. 2Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, MD 20892. * Correspondence to: Dr. Jean L. Grem, Investigational Drug Branch, National Cancer Institute, Executive Plaza North, Room 731, National Institutes of Health, Bethesda, MD 20892. Funding Information: Medical Research Council (62)",

year = "1988",

month = jul,

day = "6",

doi = "10.1093/jnci/80.9.626",

language = "English (US)",

volume = "80",

pages = "626--655",

journal = "Journal of the National Cancer Institute",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "9",

}

TY - JOUR

T1 - The role of methotrexate in osteosarcoma

AU - Grem, Jean L.

AU - King, Susan A.

AU - Wittes, Robert E.

AU - Leyland-jones, Brian

N1 - Funding Information: "Received November 23, 1987; accepted January 5, 1988. 2Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute, Bethesda, MD 20892. * Correspondence to: Dr. Jean L. Grem, Investigational Drug Branch, National Cancer Institute, Executive Plaza North, Room 731, National Institutes of Health, Bethesda, MD 20892. Funding Information: Medical Research Council (62)

PY - 1988/7/6

Y1 - 1988/7/6

N2 - High-dose methotrexate (MTX) is one of the agents currently used in intensive adjuvant chemotherapy regimens for nonmetastatic osteosarcoma. To elucidate the role of high-dose MTX in this disease, we present the history of trials conducted with MTX from the first single-agent studies through progressively complex combination regimens. With this background, some of the basic dissues concerning MTX therapy in osteosarcoma are discussed. [J Natl Cancer Inst 1988;80:626-656].

AB - High-dose methotrexate (MTX) is one of the agents currently used in intensive adjuvant chemotherapy regimens for nonmetastatic osteosarcoma. To elucidate the role of high-dose MTX in this disease, we present the history of trials conducted with MTX from the first single-agent studies through progressively complex combination regimens. With this background, some of the basic dissues concerning MTX therapy in osteosarcoma are discussed. [J Natl Cancer Inst 1988;80:626-656].

UR - http://www.scopus.com/inward/record.url?scp=0023946811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023946811&partnerID=8YFLogxK

U2 - 10.1093/jnci/80.9.626

DO - 10.1093/jnci/80.9.626

M3 - Review article

C2 - 3286880

AN - SCOPUS:0023946811

VL - 80

SP - 626

EP - 655

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 9

ER -

The role of methotrexate in osteosarcoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this